10-K: Utah Medical Products Reports 2025 Revenue, Profit Decline

Utah Medical Products Inc. reported a decline in 2025 revenues and net income, impacted by lost OEM sales and Filshie Clip litigation, despite maintaining strong cash reserves.

Summary

• Consolidated worldwide revenues for 2025 decreased by 5.8% to $38,520 thousand from $40,903 thousand in 2024.
• Net income for 2025 was $11,286 thousand, an 18.7% decrease from $13,874 thousand in 2024.
• Diluted Earnings Per Share (EPS) fell by 12.1% to $3.483 in 2025 from $3.961 in 2024.
• Gross Profit Margin contracted by 1.9 percentage points to 57.1% in 2025 from 59.0% in 2024.
• Operating Income decreased by 16.1% to $11,402 thousand in 2025.
• The revenue decline was primarily driven by a $2,295 thousand decrease in OEM sales to PendoTECH, a $310 thousand reduction from the China Deltran DPT distributor, and a $745 thousand decrease in worldwide Filshie Clip System sales.
• Cash and investment balances increased by $2,780 thousand to $85,756 thousand at year-end 2025.
• The company repurchased 148,935 shares of common stock for $8,355 thousand in 2025 and paid $3,983 thousand in cash dividends.
• Legal costs associated with Filshie clip litigation were $1,355 thousand in 2025, a decrease of $783 thousand from 2024.
• One-time G&A expenses in 2025 included a $395 thousand bad debt write-off from the China distributor and a $195 thousand loss from embezzled funds by the Australia subsidiary manager.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a cautious sentiment due to significant declines in key financial metrics (revenue, net income, EPS) in 2025 and projected negative comparative results for 1Q 2026. While the company maintains strong liquidity and anticipates a rebound, the immediate performance and ongoing legal challenges warrant a conservative outlook.

Positives

• Maintained excellent profit margins despite lower sales, with a 57.1% Gross Profit Margin and 29.3% Net Income Margin in 2025.
• Increased year-ending cash balances to $85.8 million, demonstrating strong liquidity and financial health.
• Current ratio improved significantly to 37.6 at the end of 2025 from 25.6 at the end of 2024.
• Stockholders' Equity increased by $1,841 thousand in 2025 despite substantial share repurchases and dividend payments.
• Total debt ratio remained very low at 3% at year-end 2025, with no bank debt.
• Domestic Filshie device sales increased by 10.8% and domestic NICU device sales increased by 16% in 2025.
• Legal costs associated with Filshie clip litigation decreased by $783 thousand in 2025, and 15 of 19 lawsuits have been dismissed as of March 2026.
• The identifiable intangible asset (IIA) amortization expense for Femcare will be fully amortized after 1Q 2026, leading to a $1.6 million reduction in G&A expense in 2026.
• Management projects Operating Income to increase 15-18% and EPS to be north of $4.00/share in 2026.

Negatives

• Consolidated worldwide revenues declined by 5.8% in 2025 compared to 2024.
• Net income decreased by 18.7% and diluted EPS by 12.1% in 2025.
• Gross Profit Margin contracted by 1.9 percentage points, and Operating Income Margin by 3.6 percentage points.
• Significant loss of OEM sales from PendoTECH ($2.3 million) and the China Deltran DPT distributor ($0.3 million) contributed heavily to the revenue decline.
• OUS Filshie sales decreased significantly, with OUS Direct sales down 16% and OUS distributor sales down 23%.
• The company incurred a $395 thousand bad debt write-off for a canceled order from its China distributor.
• A $195 thousand loss was recognized due to embezzlement by the Australia subsidiary manager.
• UTMD's stock substantially underperformed the DJIA, S&P 500, and NASDAQ Composite indices in both 2024 and 2025.
• Management expects 1Q 2026 to demonstrate substantially negative comparative results due to timing of revenue losses and amortization.

Risks

• Legislative or executive order healthcare interference in the United States could render the U.S. medical device marketplace unpredictable and eliminate commercial incentives for innovation.
• Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs, and diversion of management focus.
• Group purchasing organizations (GPOs) in the U.S. add non-productive costs, weaken marketing and sales efforts, and cause lower revenues by restricting access to hospitals.
• The company's value-added business strategy may not be successful in the future due to increasing complexity and uncertainty in the medical device industry.
• Growing bureaucracy in healthcare puts smaller companies like UTMD at a competitive disadvantage, leading to potential exclusion from customers due to long-term supply agreements.
• Product liability lawsuits could result in significant legal expenses and large awards against the company, particularly given the inherent risks of medical device use.
• Reliance on third-party distributors in some geographical markets can result in less predictable revenues and potential competition from cheaper, lower-quality versions of UTMD's devices.
• The loss or distraction of key employees could be disruptive to performance in a small company with limited resources.
• Fluctuations in foreign currency exchange (FX) rates relative to the USD can negatively impact USD-reported financial results, reducing sales and gross profits.
• Foreign trade restrictions, including duties, trade restrictions, and tariffs, have the potential to disrupt UTMD's supply chain and significantly affect costs.

Future Outlook

Management expects 2026 consolidated sales to be about the same as 2025, despite an anticipated zero revenue from former OEM customer PendoTECH and the China BPM kits (which totaled $2.5 million in 2025). This will be achieved by offsetting these losses with new product sales, including to other biopharma customers, modest organic growth in existing device sales, and an improvement in OUS Filshie device sales. The Gross Profit Margin is projected to expand by about one percentage point. Operating Income is expected to increase by 15-18%, and diluted Earnings Per Share are targeted to be north of $4.00, representing a 14-16% increase. The company plans to continue providing cash dividends and making opportunistic share repurchases, while remaining vigilant for accretive acquisition opportunities. However, 1Q 2026 is expected to show substantially negative comparative results due to the timing of revenue losses and the final Femcare IIA amortization expense.

Management Comments

• "UTMD's passion is in providing differentiated clinical solutions that will help improve the outcomes of medical procedures and reduce health risks, particularly for women and their babies."
• "The safety, reliability and performance of UTMD's medical devices are consistently high and represent significant clinical benefits while providing minimum total cost of care."
• "Management believes that, despite the negative impact on Return on Stockholders Equity, retaining a high cash balance increases its likelihood of being able to allow for substantial funding of any future accretive acquisition without diluting stockholder interest, as well as repurchase of UTMD shares while paying a consistent dividend, and thus will leverage stockholder value in the long term."
• "Management is focused on obtaining revenue growth in other areas to offset those losses, and achieve the same revenues in 2026 as in 2025."
• "UTMD management is committed to recapture the longer-term performance."

Industry Context

StockSavvy.ai notes that the medical device industry faces increasing regulatory burdens and consolidation in the hospital supplier environment, particularly due to Group Purchasing Organizations (GPOs) that prioritize unit price over total cost of care. This trend puts smaller, specialized companies like UTMD at a disadvantage. The company also faces competition from lower-wage manufacturers in countries like Mexico, East Europe, India, and China for OEM work. Geopolitical policies, such as tariffs, are impacting international trade and supply chains. UTMD's strategy of focusing on differentiated, high-quality products that improve patient outcomes contrasts with the industry's move towards commoditization, which presents both a challenge and an opportunity for market differentiation.

Comparison to Industry Standards

• UTMD's Filshie Clip System is empirically proven to be the safest and most effective tubal occlusive device globally, with a substantially higher probability of reversibility and a failure rate an order of magnitude less than bipolar cautery, and is simpler to perform than the Pomeroy technique.
• The Epitome electrosurgical scalpel is believed to have no close substitute for rapid, precise dissection of dense or fatty tissue, with an independent study concluding it provides a significant improvement over other devices in wound healing.
• The DELTRAN Disposable Pressure Transducer (DPT) is considered the standard in terms of accuracy, reliability, and ease of use, having been designed over thirty-five years ago.
• The Disposa-Hood for neonatal respiratory care is less invasive than nasal cannulae, avoiding potential damage to fragile tissues and maintaining a neutral thermal environment, unlike cannulae alone.
• UTMD's differentiated devices represent significant incremental improvements in patient safety, clinical outcomes, and/or total cost over preexisting clinical approaches, positioning them against more commodity-oriented competitors.

Corporate Governance

Legal Proceedings

• As of March 2026, 15 of 19 Filshie Clip System product liability lawsuits filed across federal and state courts have been dismissed, including the initial TX bellwether federal lawsuit.
• Three other court cases are currently pending decisions on summary judgment motions, which UTMD expects in 2026.
• The remaining lawsuits are filed in CT state court, where Femcare Ltd. and Utah Medical Products, Inc. have been dismissed as defendants.
• Management believes it has persuasive legal arguments in every remaining case and expects most to be dismissed by summary judgment in 2026, with a significant chance of avoiding trial.
• The company expects the outcome of the Filshie clip litigation will not be material to overall consolidated financial results, despite unusually high defense costs.
• A $195 thousand loss was recognized in 4Q 2025 due to embezzled funds by UTMD's former Australia subsidiary manager, who admitted guilt but has not yet repaid the funds.

Stakeholder Impact

• Shareholders: Experienced a 9% decline in stock value in 2025 and 27% in 2024, underperforming market indices. However, long-term stockholders have experienced excellent returns. The company continues to return cash through dividends ($1.22/share in 2025) and share repurchases ($8.355 million in 2025).
• Employees: The company's continued success depends on retaining skilled and experienced employees. Cost-of-living adjustments were implemented in 2025. All employees participate in performance-based bonus programs and sign strict confidentiality agreements.
• Customers (Clinicians/Hospitals): UTMD aims to provide high-quality, cost-effective medical devices that improve patient outcomes and safety. However, GPOs and increasing administrative burdens may restrict access to new products and limit clinician involvement in purchasing decisions.
• Suppliers: UTMD maintains good supplier relationships by paying vendors promptly and manages supply chain risk through safety stocks and alternative sourcing, anticipating potential disruptions from government policies like tariffs.
• Regulatory Authorities: UTMD is subject to extensive regulation by the FDA and other global entities, with ongoing audits and certifications (ISO13485:2016, MDSAP) to ensure compliance.

Next Steps

• Realize new sales of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers in 2026.
• Regain OUS business hindered by recent U.S. government trade policies in 2026.
• Substantially bring the Filshie Clip System product liability lawsuits in the U.S. to a favorable conclusion in 2026.
• Introduce additional products helpful to clinicians through ongoing product development in 2026.
• Continue to achieve excellent overall financial operating performance in 2026.
• Utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued in 2026.
• Remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions in 2026.

Key Dates

Recommendation

While Utah Medical Products Inc. reported a challenging 2025 with declines in revenue, net income, and EPS, the company maintains a robust financial position with significant cash reserves and no bank debt. Management's proactive steps to offset lost OEM sales, the anticipated reduction in amortization expenses, and the projected rebound in operating income and EPS for 2026 are positive indicators. The ongoing Filshie Clip litigation, though costly, is showing signs of resolution with many cases dismissed. However, the recent underperformance of the stock relative to market indices and the inherent uncertainties in achieving projected revenue offsets warrant a 'Hold' recommendation. Investors should monitor the company's ability to execute its growth strategies and the final resolution of legal proceedings before considering a stronger position.

Keywords

Medical Devices, SEC Filing, 10-K, Financial Performance, Healthcare Industry, Obstetrics, Neonatal Care, Gynecology, Electrosurgery, Urology, Filshie Clip System, Product Liability, Share Repurchases, Dividends, Regulatory Compliance, ISO13485, FDA, Biopharmaceutical, OEM Sales, International Sales